Curcumin suppresses gastric cancer by inhibiting gastrin-mediated acid secretion
Shufen Zhou¹, Dongjie Yao², Ling Guo³ and Ling Teng¹

¹ Department of Gerontology, Affiliated Second Hospital, Mudanjiang Medical University, China
² Department of Quality Control, Affiliated Second Hospital, Mudanjiang Medical University, China
³ Department of Pathology, Affiliated Second Hospital, Mudanjiang Medical University, China

Keywords
acid secretion; curcumin; gastric cancer; gastrin

Correspondence
L. Teng, Department of Gerontology, Affiliated Second Hospital, Mudanjiang Medical University, No.15 East Xiao Yun Street, Mudangjiang 157009, China
E-mail: tlandqjy@126.com

(Received 2 March 2017, revised 15 April 2017, accepted 18 April 2017)
doi:10.1002/2211-5463.12237

Gastric cancer is one of the most common malignancies in the world [1]. The 5-year survival rate of gastric cancer is extremely low. Most gastric cancer patients are diagnosed at a high clinical stage, which demands potent treatment to impede the disease progression and improve clinical outcomes. Curcumin is one of the chemotherapy drugs that have demonstrated strong efficacy in gastric cancer. Curcumin is a naturally occurring compound extracted from the rhizomes of plants in the ginger family [2]. It has a broad-spectrum therapeutic potential as a pharmaceutical agent, with antioxidative, anti-inflammatory, and anticancer properties [3]. However, despite efforts in elucidating the effects of curcumin in regulating oncogenic pathways [4], how curcumin exerts anticancer effects in gastric cancer still remains largely unknown.

It is increasingly realized that, as opposed to the alkaline condition in other tissues, an acidic environment in stomach is conducive to gastric cancer survival and development [5]. The development of gastric cancer is often accompanied by excessive secretion of acids [5–7]. It is believed that low pH environment in stomach enables gastric cancer cells to evade immune attack. It also activates genes that promote cancer cell growth, and protects cancer cells against apoptosis [8,9]. Therefore, low gastric pH is thought of as a marker for high-grade gastric cancers. Gastric acid secretion is stimulated by gastrin [10]. This is supported by the increased serum gastrin levels in high-level gastric cancer patients. This gave birth to a number of strategies to prevent cancer cell progression by reducing gastrin expression [11]. Given the anticancer efficacy of curcumin, it is possible that curcumin also regulates gastrin expression in gastric cancer. However, no evidences exist concerning whether the efficacy of

Abbreviations
CCK-8, cell-counting-Kit 8; HRP, horseradish peroxidase.
curcumin correlates to its regulation of gastric pH via gastrin secretion.

Therefore, in this study, we sought to correlate curcumin to the gastrin-mediated gastric acid secretion and investigate how this inhibits gastric cancer. To this end, we evaluated how curcumin affects gastric expression in gastric cells in vitro and in vivo. We demonstrated that curcumin was able to serve as a gastrin antagonist. Our data also indicated that gastric pH in curcumin-treated mice was higher. The data reported in this study could provide scientific ground for further clinical testing of curcumin in treating gastric cancer, strengthening the role of gastric pH in gastric cancer development.

Materials and methods

Cell culture and curcumin treatment

The human gastric cancer cell line, SGC7901, was acquired from American Type Culture Collection (ATCC, Rockville, MD, USA). Cells were cultured in the RPMI-1640 medium supplemented with 10% FBS, 100 IU·mL⁻¹ penicillin–streptomycin, 10 mM HEPES, and 2 mM glutamine. For all in vitro experiments, curcumin (Sigma-Aldrich, Saint Louis, MO, USA) was dissolved in DMSO and added to the medium at the concentration of 25 μM.

Cell proliferation assay

The proliferation of SGC7901 cells was evaluated with the cell-counting kit 8 (CCK-8) assay (Dojindo Molecular Technologies, Kumamoto, Japan) according to manufacturer’s recommendations. Briefly, SGC7901 cells were first seeded into 96-well plates (5 × 10³ cells per well). Treatment of curcumin lasted for 7 days with medium changed every 2 days. The control cells were treated with equivalent amount of DMSO. Cell viability was monitored every 2 days by incubating the cells with CCK-8 solution for 4 h, followed by measuring absorbance at 450 nm.

Annexin-V/propidium iodide double-staining assay

Cell apoptosis was evaluated by the Annexin-V/propidium iodide double-staining assay. Briefly, cells seeded in six-well plates (1 × 10⁵ cells per well) were treated with curcumin. After 3 days of treatment, cells were harvested by trypsinization and washed with PBS. Staining of the cells was performed using the Annexin-V/FITC apoptosis detection kit (Sigma, St. Louis, MO, USA) according to manufacturer’s recommendations. Cell apoptosis was quantitated on a FACScan flow cytometer (Becton Dickinson, Franklin Lakes, NJ, USA).

Western blot

Caspase-3 expression was analyzed using western blot analysis to evaluate cell apoptosis. Lysates from cells were acquired after lysis in RIPA buffer (Thermo Fisher Scientific, Waltham, MA, USA). Quantitation of protein content was carried out using the bicinchoninic acid assay (Abcam, Cambridge, MA, USA). Protein (50 μg) was resolved using SDS/PAGE, followed by being electrotransferred onto PVDF membranes. Blocking was performed in 1% BSA solution. Primary antibodies for caspase-3 and GAPDH were acquired from Abcam, which were used to incubate the membranes overnight at 4 °C. TBST (0.1% tween-20) was used to wash the membranes. Appropriate horseradish peroxidase (HRP)-conjugated secondary antibodies diluted in TBST were then added to the membrane. Bound antibodies were visualized using an enhanced chemiluminescence ECL reagent (Pierce, WI, USA) and imaging using the ChemiDoc imaging system (Abcam). Protein band intensities were quantitated using IMAGEJ (NIH, Bethesda, MD, USA), which were normalized to the level of GAPDH.

Animal experiments

All animal experiments were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals, and were approved by the Institutional Animal Care and Use Committee (IACUC) of Affiliated Second Hospital, Mudanjung Medical College. The Balb/c nude mice were purchased from Nanjing Model Animal Center. SGC7901 cells (1 × 10⁵) were subcutaneously injected into the left foreleg to initiate gastric cancer xenografts [12]. Curcumin dissolved in DMSO were orally administered into the mouse (100 mg·kg⁻¹). The death, suffering, sick, moribund, and skinniness of the mice were documented to analyze survival. For measurement of gastric pH, mice were anaesthetized under isoflurane and stomachs were excised. The pH of gastric content was measured by immersing a pH probe in the gastric content. Mice undergone pH measurement were sacrificed immediately afterward experiments. After a 2-month treatment, blood samples were collected by drawing from the heart and mice were sacrificed in a CO₂ chamber. The tumor sizes were recorded. Blood samples were centrifuged at 1500 g for 15 min and stored in −20 °C before use. Gastrin levels in serum were analyzed with ELISA (Abcam) according to manufacturer’s recommendations.

Statistical analysis

All experiments were performed in triplicates. Data were represented as mean ± SD. Analysis of the data was performed using one- or two-way ANOVA analysis followed by a post hoc test using the spss software (SPSS Inc.,
Results

Curcumin inhibits gastric cancer cell proliferation and induces cell apoptosis

Firstly, dose-dependent effects of curcumin on the growth of gastric cancer cell line were studied. It was found that the dose of curcumin at 25 μM was the lowest dose to suppress the growth of gastric cancer cell line to the most extent (Fig. S1). Thus, the dose of 25 μM was chosen for the following studies. To further confirm the antitumor effects of curcumin, we incubated gastric cancer cells with 25 μM curcumin followed by evaluation of cell proliferation and apoptosis. As shown in Fig. 1A, significant inhibition on cell proliferation was observed. In line with this, curcumin-treated gastric cancer cells also demonstrated higher apoptotic activity (Fig. 1B) based on Annexin V/propidium iodide double-staining assay. Western blot analysis confirmed that caspase-3 level, which is positively correlated with apoptosis, was significantly upregulated compared to that of untreated cells (Fig. 1C).

Acidification promotes gastric cancer cell proliferation and protects cells from apoptosis

We then examined if low pH promotes gastric cancer survival and progression. We added hydrochloric acid to the cell culture medium to adjust the pH to 6.4. It was found that this acidified environment resulted in increased gastric cancer cell proliferation (Fig. 2A). However, incubation with curcumin, with acidification, led to lower gastric cancer cells proliferation (Fig. 2A). Meanwhile, while gastric cancer cells under acidification demonstrated lower apoptosis, as evidenced by lower apoptosis rate and caspase-3 expression (Fig. 2B,C), treatment of curcumin counteracted this dampened apoptosis. Therefore, curcumin was able to potently antagonize the tumor-promoting effects of acidification.

Curcumin inhibits gastrin secretion

Gastrin is a putative regulator of gastric acid secretion. As our data indicated an antagonizing role of curcumin against acidification, it is imperative to confirm if curcumin lowers gastrin secretion. To this end, gastrin secretion by gastric cancer cells under curcumin treatment was assessed. While gastrin was abundantly secreted by gastric cancer cells, gastrin level in the medium of curcumin-treated cells was much lower than that in untreated cells (Fig. 3A). Following this, we added proglumide, a gastrin antagonist, into the culture medium. Expectedly, the proliferation of gastric cancer cells was also suppressed but the suppressive effect was weaker than that of curcumin. Interestingly, proglumide slightly compromised the antiproliferative ability of curcumin (Fig. 3B). This is possibly due to the fact that proglumide competed with curcumin in inhibiting gastrin. In agreement to
this, Annexin V/propidium iodide double-staining assay showed that apoptosis levels in proglumide-treated gastric cancer cells were elevated, but curcumin-treated gastric cancer cells did not show significant elevation of apoptosis after treatment with proglumide (Fig. 3C). Western blot analysis of gastric cancer cells in the apoptotic gene capase-3 inhibition of gastrin confirmed that curcumin exerts its antitumor effects by promoting apoptosis (Fig. 3D).

Fig. 2. Acidity promoted the growth of gastric cancer cell line by the treatment with curcumin. (A) The SGC7901 cells were placed on 96-well plates (1 × 10^4 cells per well) and incubated with fresh medium as control group or containing 25 μM curcumin as treated group. Meanwhile, these two group of cells were, respectively, regulated to pH 6.4 by adding HCL solution. Growth curves of individual curcumin-treated or not and acidulated SGC7901 cells or not from the same original cell numbers were detected by CCK-8 kit. OD value was measured at 450 nm and data demonstrated a significant growth increase in acidic condition (**P < 0.01 and *P < 0.05). (B) Annexin-V/propidium iodide double-staining assay was performed to detect the apoptosis levels of curcumin-treated or not and acidulated SGC7901 cells or not. (C) Caspase-3 gene expression of curcumin-treated or not and acidulated SGC7901 cells or not were analyzed by WB. The data also demonstrated a significant apoptotic decrease in acidic condition (**P < 0.01).

Fig. 3. Curcumin suppressed the secretion of gastrin in gastric cancer cell line. (A) The SGC7901 cells were placed on six-well plates (1 × 10^5 cells per well) and incubated with fresh medium as control group or containing 25 μM curcumin as treated group. Gastrin level was detected by PCR in curcumin-treated and nontreated SGC7901 cells after the culture for 48 h. Relative expression values represent mean and SD from three independent experiments (**P < 0.01). The data demonstrated a significant decrease in gastrin by curcumin. (B) Growth curves of individual curcumin-treated or not and proglumide-treated or not of SGC7901 cells from the same original cell numbers were detected. OD value was measured at 450 nm and data demonstrated a significant growth decrease by proglumide, but no difference for curcumin-treated cells. (C) Annexin-V/propidium iodide double-staining assay was performed to detect the apoptosis levels of curcumin-treated proglumide-treated or not of SGC7901 cells. The data demonstrated a significant apoptotic increase by proglumide (**P < 0.01), but no difference for curcumin-treated cells. (D) Caspase-3 gene expression also was analyzed by WB. The data also demonstrated a significant apoptotic increase by proglumide (**P < 0.01), but no difference for curcumin-treated cells.
Curcumin inhibits of gastric cancer in vivo

Gastric cancer cell lines were subcutaneously injected into mice to initiate gastric cancer xenografts. Curcumin was given at the dose of 100 mg·kg⁻¹ for 2 weeks and the tumor-bearing mice without treatment were used as controls. Tumor growth was monitored and survival data of mice were acquired. We show that curcumin treatment led to a substantially higher survival (Fig. 4A). Consistently, tumors of curcumin-treated mice were significantly smaller than those of untreated mice (Fig. 4B). Annexin V/propidium iodide double-staining assay indicated that tumor apoptosis in curcumin-treated mice was significantly higher than that in untreated mice (Fig. 4C). Capase-3 was significantly higher in untreated tumor tissue than in untreated tumor tissue (Fig. 4D).

Curcumin inhibits gastrin and gastric acid secretion

During the animal study, serum gastrin was monitored. We show that with curcumin treatment, gastrin secretion was significantly reduced (Fig. 5A). Concomitantly, the pH value of gastric fluid of the curcumin-treated mice was significantly higher than that of the untreated mice (Fig. 5B). This confirms that curcumin lowers gastrin secretion to elevate gastric fluid pH, which inhibits gastric cancer progression.

Discussion

Curcumin is a polyphenol with excellent safety, tolerability, and nontoxicity that have been demonstrated in clinical trials. Thus far, curcumin has shown therapeutic potential in a wide range of human disorders [13]. Here, we corroborated that curcumin potently inhibits gastric cancer growth both in vitro and in vivo, accompanied by significant gastrin downregulation and hypoacidity in stomach. Previously, the potential of curcumin in regulating gastric cancer was thought attributable to downregulation of oncogenic pathways, such as PAK1 and cyclin D1 pathways [2]. Curcumin was also shown to reverse chemoresistance of gastric cancer by downregulating the NF-kB pathway [14]. These findings are consistent with the role of curcumin as an immunosuppressant by regulating cytokine production and immunological gene pathways to inhibit cancer progression.

Thus far, whether curcumin affects acid production in gastric cancer is unclear. It is increasingly realized that the acid environment in stomach promotes gastric cancer. Previously, the link between gastric acid and bacteria-induced gastric diseases has been established. Hyperacidity causes injury to stomach, and in severe conditions, ulcer may develop. Infections in the
stomach may result in chronic inflammation that increases risk of carcinogenesis. In addition, hyperacidity was shown to promote *Helicobacter pylori* infection, which is a significant cancer inducer [15]. Increased gastric juice acidity is also associated with higher risk of hiatal hernia-related gastric diseases [16]. In cancer, low pH environment favors the formation of hypoxia, which is well-known for conferring cancer resistance to chemotherapies [17]. Indeed, our data showed an increased proliferation of gastric cancer cells under low pH. The inducer of acid secretion, gastrin, is proven a valuable biomarker in the screening of gastric cancer [18,19]. Gastric cancer cells overexpress gastrin as a way to remodel microenvironment to facilitate the outgrowth and metastases. Our data indicate that gastrin secretion is markedly inhibited by curcumin treatment. This is consistent with a recent study showing that curcumin protects against gastric mucosa by inducing hypoacidity in the stomach [20]. Our *in vivo* data also indicate that gastric pH is significantly increased during curcumin treatment. To our knowledge, this is the first time that the anticancer effects of curcumin have been associated with its effects in inducing hypoacidity in stomach. It is also worth noting that curcumin is better tolerated than other acid suppressive drugs in that curcumin treatment is not associated with adverse effects, such as pneumonia [21], commonly seen for other acid suppressive drugs.

We showed that curcumin reduces gastrin secretion by gastric cancer cells. Similar to proglumide, curcumin acts as an antagonist to gastrin and curcumin demonstrated superior anticancer efficacy in gastric cancer compared to proglumide. In gastric cancer, gastrin is responsible for not only inducing acid secretion but also stimulating a number of oncogenic pathways, such as cyclin D1 and β-catenin pathways [22], to induce cancer progression. Therefore, it can be speculated that by suppressing gastrin secretion, curcumin disrupts a cascade of cancer-related events to impede the development of cancer. In line with this, we demonstrated that higher apoptotic activity was seen in curcumin-treated gastric cancer cells. This echoes with the clinical data showing that patients treated with curcumin demonstrated lower gastrin secretion, as well as decreased tumor burden. Our study is paralleled by efforts in developing gastric antagonists or gastrin receptor antagonists to retard tumor progression [11]. Besides, gastrin also plays an important role in other cancers, such as pancreatic cancer [23] and other malignancies, such as natriuresis and diuresis [24]. By suppressing gastrin expression, curcumin should also exert ameliorating effects in these malignancies as well.

Currently, curcumin is not yet tested in clinical treatment of gastric cancer. Our study demonstrated that cancer cell proliferation was inhibited and apoptosis activity was increased by curcumin treatment. Our data extend our knowledge on the mechanism of curcumin in retarding gastric cancer progression, and could possibly give rise to new applications of curcumin based on its effects in regulating gastrin and gastric pH. Its nontoxicity and great tolerability also potentiate it as a chemopreventative drug and its regulation on immunological response, oxidative stress, etc., could also benefit patients with nonlethal diseases, such as hiatal hernia and *H. pylori* infections.

**Author contributions**

SZ, DY, and LG acquired the data, analyzed, and interpreted the data. LT conceived, designed the project, and wrote the paper.

**References**

1. Rugge M, Fassan M & Graham DY (2015) Epidemiology of gastric cancer. In: *Gastric Cancer*. Springer, New York, NY.
2. Cai X-Z, Wang J, Xiao-Dong L, Wang G-L, Liu F-N, Cheng M-S and Li F (2009) Curcumin suppresses
Curcumin inhibits gastric cancer progression

S. Zhou et al.

proliferation and invasion in human gastric cancer cells by down-regulation of PAK1 activity and cyclin D1 expression. Cancer Biol Ther 8, 1360–1368.

Zheng R, Deng Q, Liu Y and Zhao P (2017) Curcumin inhibits gastric carcinoma cell growth and induces apoptosis by suppressing the Wnt/beta-catenin signaling pathway. Med Sci Monit 23, 163–171.

Xue X, Yu J-L, Sun D-Q, Kong F, Qu X-J, Zou W, Wu J and Wang R-M (2014) Curcumin induces apoptosis in SGC-7901 gastric adenocarcinoma cells via regulation of mitochondrial signaling pathways. Asian Pac J Cancer Prev 15, 3987–3992.

Takeuchi H, Maehara Y, Tokunaga E, Koga T, Kakeji Y and Sugimachi K (2003) Prognostic value of preoperative immunosuppressive acidic protein levels in patients with gastric carcinoma. Hepatogastroenterology 50, 289–292.

Deng K, Lin S, Zhou L, Li Y, Chen M, Wang Y and Li Y (2012) High levels of aromatic amino acids in gastric juice during the early stages of gastric cancer progression. PLoS One 7, e49344.

Deng K, Lin S, Zhou L, Geng Q, Li Y, Xu M and Na R (2011) Three aromatic amino acids in gastric juice as potential biomarkers for gastric malignancies. Anal Chim Acta 694, 100–107.

Estrella V, Chen T, Lloyd M, Wojtkowiak J, Cornnell HH, Ibrahim-Hashim A, Bailey K, Balagurunathan Y, Rothberg JM and Sloane BF (2013) Acidity generated by the tumor microenvironment drives local invasion. Can Res 73, 1524–1535.

Taylor S, Spugnini EP, Assaraf YG, Azzarito T, Rauch C and Fais S (2015) Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach. Drug Resist Updates 23, 69–78.

Kosugi Y, Yamamoto S, Sano N, Furuta A, Igarı T, Fujioka Y and Amano N (2015) Evaluation of acid tolerance of drugs using rats and dogs controlled for gastric acid secretion. J Pharm Sci 104, 2887–2893.

Hoosen NM, Kiener PA, Curry RC, Rotavi LC, Megilibra DK and Brattain MG (1988) Antiproliferative effects of gastrin receptor antagonists and antibodies to gastrin on human-colon carcinoma cell-lines. Can Res 48, 7179–7183.

Zhang J, Kou YB, Zhu JS, Chen WX and Li S (2014) Knockdown of HMGB1 inhibits growth and invasion of gastric cancer cells through the NF-kappaB pathway in vitro and in vivo. Int J Oncol 44, 1268–1276.

Gupta SC, Patchva S and Aggarwal BB (2013) Therapeutic roles of curcumin: lessons learned from clinical trials. Aaps J 15, 195–218.

Yu L-L, Wu J-G, Dai N, Yu H-G and Si J-M (2011) Curcumin reverses chemoresistance of human gastric cancer cells by downregulating the NF-kB transcription factor. Oncol Rep 26, 1197.

Hatakeyama M (2014) Helicobacter pylori CagA and gastric cancer: a paradigm for hit-and-run carcinogenesis. Cell Host Microbe 15, 306–316.

Kishikawa H, Kimura K, Ito A, Arakata K, Takarabe S, Kaida S, Kanai T, Miura S and Nishida J (2017) Association between increased gastric juice acidity and sliding hiatal hernia development in humans. PLoS ONE 12, e0170416.

Samanta D, Gilkes DM, Chaturvedi P, Xiang L and Semenza GL (2014) Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells. Proc Natl Acad Sci USA 111, E5429–E5438.

Nejadi-Kelarijani F, Roshandel G, Semnani S, Ahmadi A, Faghani B, Besharat S, Akhavan-Tabib A and Amiriani T (2014) Diagnostic values of serum levels of pepsinogens and gastrin-17 for screening gastritis and gastric cancer in a high risk area in Northern Iran. Asian Pac J Cancer Prev 15, 7433–7436.

Waldum HL (2017) Gastrin and gastric cancer. Front Endocrinol 8, 1.

Czekaj R, Majka J, Ptak-Belowska A, Szlachcie A, Targosz A, Magierowska K, Strzalka M, Magierowski M and Brzozowski T (2016) Role of curcumin in protection of gastric mucosa against stress-induced gastric mucosal damage. Involvement of hypoaicidity, vasoactive mediators and sensory neuropeptides. J Physiol Pharmacol 67, 261–275.

Laheij RJ, Sturkenboom MC, Hassing R-J, Dieleman J, Stricker BH and Jansen JB (2004) Risk of community-acquired pneumonia and use of gastric acid–suppressing drugs. JAMA 292, 1955–1960.

Pradeep A, Sharma C, Sathyarayana P, Albanese C, Fleming JV, Wang TC, Wolfe MM, Baker KM, Pestell RG and Rana B (2004) Gastrin-mediated activation of cyclin D1 transcription involves beta-catenin and CREB pathways in gastric cancer cells. Oncogene 23, 3689–3699.

Smith JP, Fonkoua LK and Moody TW (2016) The role of gastrin and CCK receptors in pancreatic cancer and other malignancies. Int J Biol Sci 12, 283.

Chen Y, Asico LD, Zheng S, Van Anthony MV, He D, Zhou L, Zeng C & Jose PA (2015) Gastrin and D1 dopamine receptor interact to induce natriuresis and diuresis. J Hypertens, 33(suppl 1), e86.

Supporting information

Additional Supporting Information may be found online in the supporting information tab for this article: Fig. S1. Curcumin dose-dependent suppressed the growth of gastric cancer cell line.